Glaxosmithkline Plc and Novartis AG in Consumer Health: Prospects for Their New Joint Venture

Company Profile

About This Report

Sep 2014

Among the largest pharmaceutical companies, both GlaxoSmithKline Plc and Novartis AG are global leaders in consumer health. While manufacturing disruptions and unfavourable market conditions in key geographies have hindered recent performance, these companies have taken steps to promote future success. In April 2014, GSK and Novartis announced plans to create a consumer health joint venture to be completed in the first half of 2015 that has the potential to become the new global industry leader.

Want to find out more about this report?
Request more information
Why buy this report?

Gain competitive intelligence about market leaders. Track key industry trends, opportunities and threats. Inform your marketing, brand, strategy and market development, sales and supply functions.

Your Recently Viewed Reports

Glaxosmithkline Plc and Novartis AG in Consumer Health: Prospects for Their New Joint Venture

Euromonitor International's report on GlaxoSmithKline Plc delivers a detailed strategic analysis of the company's business, examining its performance in the Vitamins and Dietary Supplements market and the global economy.

Company and market share data provide a detailed look at the financial position of GlaxoSmithKline Plc, while in-depth qualitative analysis will help you understand the brand strategy and growth prospects of GlaxoSmithKline Plc.

This report examines:
  • Company share by region and sector
  • Brand portfolio
  • New product developments
  • Marketing and distribution strategies

A detailed SWOT analysis of GlaxoSmithKline Plc provides strategic intelligence on:
  • Strengths and weaknesses
  • Category and country opportunities for growth
  • Challenges and threats from current competition and future prospects
  • Global and regional market positions

Research You Can Trust:

Euromonitor International's company profile reports are written by our Vitamins and Dietary Supplements research team, a dedicated group of analysts that knows the industry inside and out.

Buy this report to inform your planning, strategy, marketing, sales and competitor intelligence functions.

Delivery format

Reports are delivered in PDF format and can be downloaded from your online account immediately after purchase.

Introduction

Scope
Merger and acquisition activity in the consumer health industry

Glaxosmithkline Plc in Consumer Health: Strategic Evaluation

Key company facts
GlaxoSmithKline across the consumer products universe
Prioritising operational simplicity and portfolio optimisation

Glaxosmithkline Plc in Consumer Health: Competitive Positioning

GlaxoSmithKline growth relative to the consumer health industry

Glaxosmithkline Plc in Consumer Health: Competitive Positioning

GlaxoSmithKline in global consumer health
GSK development in key consumer health categories

Glaxosmithkline Plc in Consumer Health: Market Assessment

GSK’s high concentration within analgesics

Glaxosmithkline Plc in Consumer Health: Market Assessment

Asia Pacific: Diversification limits damage in China

Glaxosmithkline Plc in Consumer Health: Brand Strategy

GSK: Leading consumer health brands

Glaxosmithkline Plc in Consumer Health: Brand Strategy

Panadol’s growing global presence

Novartis AG in Consumer Health: S trategic Evaluation

Key company facts

Novartis AG in Consumer Health: Strategic Evaluation

On the road to recovery

Novartis AG in Consumer Health: Competitive Positioning

Novartis growth relative to the consumer health industry
Novartis in global consumer health
Novartis development in key consumer health categories

Novartis AG in Consumer Health: Market Assessment

Eye care on the rise
A tale of two markets: Emerging vs developed

Novartis AG in Consumer Health: Brand Strategy

Novartis: Leading consumer health brands
Voltaren : Growth seen around the world

Prospects for the Glaxosmithkline Consumer Healthcare Joint Venture: Operations

The 3-part transaction between GSK and Novartis

Prospects for the Glaxosmithkline Consumer Healthcare Joint Venture: Competitive Positioning

Number six and seven together may become the new number one
The evolving consumer health competitive landscape

Prospects for the Glaxosmithkline Consumer Healthcare Joint Venture : Geographic and Category Opportunities

Joint venture category strengths
New analgesics portfolio to reflect market demand
Brand diversification in cough, cold and allergy remedies
The complex NRT smoking cessation aids market
A truly global presence
GSK and Novartis consumer health country coverage
US: Recovery key to success
Taking advantage of the extensive global distribution network

Prospects for the Glaxosmithkline Consumer Healthcare Joint Venture: Strategic Evaluation

SWOT: GlaxoSmithKline Consumer Healthcare joint venture

Data Parameters and Report Definitions

Data parameters and report definitions